Kaiser Permanente to Evaluate Neopath's AutoPap 300 QC System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

REDMOND, Wash--NeoPath Inc has signed an agreement with Kaiser Permanente to install AutoPap 300 QC Systems at its Northern California facility. Following a successful evaluation, Kaiser Permanente anticipates making the technology available to its nearly 2.5 million Northern California members.

REDMOND, Wash--NeoPath Inc has signed an agreement with KaiserPermanente to install AutoPap 300 QC Systems at its Northern Californiafacility. Following a successful evaluation, Kaiser Permanenteanticipates making the technology available to its nearly 2.5million Northern California members.

The AutoPap System rescreens Pap smear slides initially classifiedas normal, using high-speed image processing computers, videoimaging technology, and image interpretation software. In clinicaltrials in US laboratories, the system improved the detection rateof false-negative smears.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content